Kornimate/medical-research-clean huggingface dataset:
treatment of atrophic gastritis after hp eradication with modified liujunzi decoction based on syndrome differentiation

Conditions: Chronic Atrophic Gastritis

Summary: this is an observational cohort study of clinical efficacy study.the purpose of this topic is to evaluate the efficacy and safety of modified liujunzi decoction based on syndrome differentiation in patients with chronic atrophic gastritis(cag) after hp eradication.taking modified liujunzi decoction as the observation group and weifuchun routine treatment as the control group, so as to provide evidence for the treatment of cag and reduce the risk of gastric cancer. a total of 284 patients were included. the curative efficacy, symptom score and adverse events will be recorded and analyzed.


Eligibility criteria:
inclusion criteria: * patients with cag diagnosed by endoscopy and pathological examination, the pathological diagnosis criteria refer to the china consensus of chronic gastritis (2017) ; * previous hp infection, hp negative after standardized treatment; * tcm syndrome differentiation mainly focuses on the weakness of the spleen and stomach,referring to the consensus on the diagnosis and treatment of chronic atrophic gastritis with integrated traditional chinese and western medicine (2017), there is no restriction on concurrent syndrome; * age 18-70 years old, regardless of gender; * the subject (or legal representative) voluntarily agreed and signed the informed consent form, and was able to abide by the study protocol during the study. exclusion criteria: * history of gastric surgery; * combined with serious diseases affecting the study evaluation, such as serious liver disease, heart disease, kidney disease, malignant tumor and alcoholism; * allergic to the drugs used in this study; * participated in clinical research of other drugs in the first 3 months of the study; * patients can't express correctly their subjective feelings and can't cooperate.

Keywords: chronic atrophic gastritis modified liujunzi decoction treatment based on syndrome differentiation clinical study efficacy cohort study
a phase 1b study of sgn-75 in combination with everolimus in patients with renal cell carcinoma

Conditions: Renal Cell Carcinoma

Summary: this is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of sgn-75 in combination with everolimus in patients with cd70-positive metastatic renal cell carcinoma.


Eligibility criteria:
inclusion criteria: * diagnosis of metastatic renal cell carcinoma with confirmed cd70 expression * previously treated with at least 1 tyrosine kinase inhibitor (tki) * measurable disease * eastern cooperative oncology group performance status 0 or 1 * adequate lung and renal function exclusion criteria: * prior treatment with anti-cd70-directed therapy * received more than one prior treatment with an mtor inhibitor

Keywords: antibody-drug conjugate monomethylauristatin f carcinoma, renal cell antigens, cd70 drug therapy
efficacy of preoperative bevacizumab for diabetic eye disease

Conditions: Proliferative Diabetic Retinopathy

Summary: reports of the use of intravitreal bevacizumab (avastin, genentech) for the reduction of neovascularization in proliferative diabetic retinopathy have demonstrated significant regression in the number of new vessels. reducing the vascularity of neovascular fibrovascular tissue can potentially reduce bleeding intraoperatively and thus facilitate the vitrectomy procedure. the investigators chose to investigate the potential benefit of the use of preoperative bevacizumab in the management of these most complex cases.

purpose: to evaluate the role of preoperative intravitreal bevacizumab as an adjunct to vitrectomy in the management of severe diabetic eye disease. settings: kasr el-aini teaching hospital - cairo university from 2007 to 2008. methods: twenty eyes of 19 patients with severe proliferative diabetic retinopathy were recruited into the study. all eyes underwent a single intravitreal injection of bevacizumab 1.25 mg in 0.05 ml one week prior to vitrectomy for tractional (14), combined tractional/rhegmatogenous retinal detachment (4), and fibrovascular tissue covering/distorting the macula (2). exclusion criteria were: previous vitrectomy, neovascular glaucoma, and dense media opacity (dense cataract and vitreous hemorrhage) precluding fluorescein angiography (fa) that was done pre- and 1 week post injections. best corrected visual acuity (bcva), anterior segment with dilated fundus examinations, and intraocular pressures (iop), were done pre-, 1 week post-injections, 1 day, 1 week and monthly for 3 months post-vitrectomy. intra- and post-operative bleedings were recorded.

Eligibility criteria:
inclusion criteria: * tractional retinal detachment involving or threatening the macula, * tractional+rhegmatogenous retinal detachment, or * fibrovascular tissue covering and distorting the macula. exclusion criteria: * vitrectomy * neovascular glaucoma * dense media opacity (dense cataract and vitreous hemorrhage) precluding fluorescein angiography (fa)

Keywords: proliferative diabetic retinopathy vitrectomy bevacizumab
machado-joseph disease in israel

Conditions: Spinocerebellar Ataxia 3

Summary: machado-joseph disease (mjd) or spinocerebellar ataxia type 3 (sca-3) is the most common dominant ataxia. the genetic cause of this late-onset degenerative disorder is the expansion of a (cag)n tract located in the exonic region of the atxn3 gene. in 1994 the first case of mjd among the yemenite jewish subpopulation living in israel was published. the puropse of this study is to describe the clinical phenotype and genotype of the yemenite jewish subpopulation with mjd living in israel


Eligibility criteria:
inclusion criteria: * spinocerebellar ataxia 3 yemenite jews patients exclusion criteria: * all others
a high school program for preventing prescription drug abuse

Conditions: Prescription Drug Abuse (Not Dependent); Substance Use; Substance Abuse

Summary: this project will develop and evaluate a program to prevent prescription drug abuse in high school students

this fast-track sbir project is designed to address the critical need for an effective primary prevention approach for prescription drug abuse (pda), an urgent public health crisis in the united states. the project involves developing and testing an innovative new approach to the primary prevention of pda among high school students utilizing e-learning and small group facilitator-led intervention modalities. the intervention is an adaptation of the evidence-based substance abuse prevention approach called life skills training (lst). the adapted intervention will address the relationship between pda and alcohol, tobacco and other drug (atod) use and abuse; positively change social norms surrounding atod and pda; discourage diversion of prescription medications; enhance protective factors by building social and self-regulation skills through interactive learning and behavioral rehearsal scenarios.

Eligibility criteria:
inclusion criteria: * high school aged-youth exclusion criteria: * significant cognitive impairment or severe learning disabilities, as screened by field staff at participating sites
nafld: independent effects of western dietary pattern profile and sedentary life

Conditions: Fatty Liver

Summary: investigators perform a counseling intervention study (6 months) in adult subjects with evidence of fatty liver by ultrasound, graded 0-3 according to the bright liver score (bls); exclusion criteria are diabetes, renal insufficiency (glomerular filtration rate \ ii nyha ( new york heart association) class), chronic virus hepatitis, and cirrhosis. insulin resistance was assessed as homeostasis model assessment-insulin resistance (homa-ir) . suggestions and advice on individual "healthy" food purchase, storage, and cooking were given. reliable feedback and evidence of patients' adherence were obtained by scheduled dietician's interviews. investigators will challenge the predictive effects of the adherence to mediterranean diet, of western dietary profile score and of increased physical activity at 6 months in a body mass index changes-balanced model to detect independent effects, if any, of the studied variable on nafld persistence, amelioration or disappearance. threshold and odds of mediterranean and western dietary profile score will be calculated by contingency tables and receiver operator characteristic curve (roc) analysis..

dietary and physical exercise counseling.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of fatty liver exclusion criteria: * type i or type ii diabetes, * no alcohol, cancer, malnutrition, severe obesity, renal insufficiency, viral hepatitis, other chronic disease
darwin study: a randomization/withdrawal efficacy study of dexloxiglumide in constipation-predominant irritable bowel syndrome (c-ibs)

Conditions: Irritable Bowel Syndrome

Summary: irritable bowel syndrome (ibs) is the most commonly identified functional gastrointestinal disorder, affecting 10-20% of the population in the western world, seen predominantly in females and with a negative impact on quality of life, characterized by recurrent and often disabling abdominal pain associated with altered frequency or appearance or passage of the stool. ibs aetiology is unknown and its treatment remains largely empirical and directed to the relief of symptoms. one possible target for ibs treatment has been identified in drugs that modulate the action of cholecystokinin (cck), a peptide gut hormone implicated in the regulation of motor and sensory functions at various levels of the gastrointestinal tract. the biological actions of cck in the gastrointestinal tract are mediated by cck1-receptors. dexloxiglumide is an oral potent and selective antagonist of cck1-receptors. the mechanism by which dexloxiglumide might be beneficial in ibs is its ability to modulate visceral hypersensitivity and gut dysmotility. the darwin study has been designed to confirm the efficacy of dexloxiglumide according to a so-called randomized/withdrawal design. in this design all participants start the study treatment and only improved patients (the "responders") are randomized to active treatment or placebo, expecting a more frequent and/or a more rapid relapse of their symptoms in patients randomised to placebo than those on active. female and male patients, aged 18-70 yrs meeting ibs diagnostic criteria whose main complain is constipation, with a disease of at least moderate severity, will receive dexloxiglumide or placebo during a double-blind treatment phase of 24 weeks, following a first treatment of up to 12 wks during which patients will have to qualify as "responders" to the study treatment. the responder status of each patient over each 4-wk assessment period, will be based on a weekly global patient-based assessment of relief and control of symptoms using a telephone/internet-based diary. additional secondary efficacy parameters will include: effect of treatment on ibs cardinal symptoms (e.g. abdominal discomfort/pain, bloating, straining, incomplete evacuation, urgency, stool frequency and consistency), on rescue laxative consumption, and on quality of life. standard safety parameters include vital signs, adverse event reporting, physical examination, routine laboratory screen, 12-lead ecg and gallbladder ultrasound.


Eligibility criteria:
inclusion criteria: * rome ii criteria for ibs and manifesting supportive symptoms for the sub-classification of c-ibs, with a disease of at least moderate severity. exclusion criteria: * standard exclusions apply

Keywords: irritable bowel syndrome cholecystokinin dexloxiglumide randomized/withdrawal
analyzing the effect of air polishing on tooth surfaces with two imaging methods

Conditions: Dental Plaque

Summary: micro-ct is a non-destructive imaging method with high resolution and allows to examine all tooth structures individually. pre- and post-application images obtained by micro-ct can be superimposed and differences can be precisely detected. intraoral scanners in cad/cam systems also provide non-destructive image scanning. cad/cam are systems that are widely used in dentistry today. access to the device is easier than micro-ct. this study was focused on to compare two different imaging methods by assessing changes caused by sodium bicarbonate and glycine air polishing on the tooth surfaces.

the patients were recruited from individuals seeking periodontal and/or dental treatment at kocaeli university, faculty of dentistry. the teeth samples were collected from the participants who have a single-rooted tooth with the gingival recession on all surfaces and need to be extracted. all patients who met the criteria were informed about the study. patients who gave written informed consent were included. before the teeth extractions, root surfaces were marked with a bur at the level of the gingival margin. extractions were performed under local anesthesia with 2% xylocaine adrenalin. fourteen single root extracted teeth were included into the study. the crown and exposed root surface were air polished using glycine and sodium bicarbonate powders at instrumentation time of 5s, combinations of medium and maximum power and medium water settings, distance of 5mm and angulation of 60 degree. samples were scanned before and after air polishing with a high-resolution micro-ct device. the scanning conditions were 100 kvp; 100-ma, 0.5-mm al/cu filter; 13.1-μm pixel size; and rotation at 0.2 steps. according to the manufacturer's instructions, each sample was rotated 360°. the mean scanning time was around 1hour. the teeth surfaces were digitalized before and after air polishing with an intraoral scanner. the mean scanning time was around 10 second. the virtual images of the scanned teeth were saved in stereolithography (stl) format. the defect volume was estimated. the data were analyzed using commercially available statistical analysis software. descriptive statistics that were used to analyze the results included the mean, standard deviation, median, minimum, and maximum. mann-whitney u test was performed to compare differences between two independent variables. wilcoxon test was used to compare differences between two dependent variables. p-values less than 0.05 were considered statistically significant.

Eligibility criteria:
inclusion criteria: being older than age of 18, willing to participate the study, to have a single rooted tooth with gingival recession on all surfaces and need to be extracted, the tooth has to be free of caries, defects and restorations. exclusion criteria: have history of infectious diseases like hepatitis and/or hiv (+).

Keywords: computer-aided design x-ray microtomography sodium bicarbonate glycine air abrasion
liver cancer immunotherapy: placebo-controlled clinical trial of hepcortespenlisimut-l

Conditions: Hepatocellular Carcinoma; HCC; Liver Cancer

Summary: phase iii, randomized, placebo-controlled, double-blinded trial aimed to seek the therapeutic benefit of hepcortespenlisimut-l (hepko-v5) in subjects with advanced hepatocellular carcinoma.

phase iii, randomized, placebo-controlled, double-blinded trial aimed to seek the therapeutic benefit of hepcortespenlisimut-l (hepko-v5) in subjects with advanced hepatocellular carcinoma. the results will be compared to placebo. the trial duration is 3 months and will consist of one stage with baseline laboratory evaluation including afp levels with follow-up at monthly intervals. in addition pre-entry abdominal ct scan and end-study ct scan will be preformed. the clinical evaluation will be quantified according to special performance questionnaire.

Eligibility criteria:
inclusion criteria: subjects who are at least 18 years old and are willing and capable of providing informed consent. both men and non-pregnant women will be included. hcc diagnosis documented prior to study entry by either cytology/histology, ct scan, and afp serum test higher or equal to 30 iu/ml. all subjects with reproductive potential are advised to utilize effective contraception throughout the course of this study. health score status at baseline. agreement to participate in the study and to give at least 3 samples of blood for lab tests. readily available home or o other address where patient can be found. - exclusion criteria: subjects who might have already taken v5 in prior trials and have no baseline data. those who met inclusion criteria can be retrospectively enrolled. pregnant or breast-feeding women are excluded. subjects who have taken other immunomodulatory therapies within 2 months prior to entry: systemic corticosteroids, immune globulin (iv gamma globulin, ivig), interferons, interleukins, pentoxifylline (trental), thalidomide, filgrastim (g-csf), sargramostim (gm-csf); dinitrochlorobenzene (dncb), thymosin alpha 1 (thymosin alpha), thymopentin, inosiplex (isoprinosine), polyribonucleoside (ampligen), ditiocarb sodium (imuthiol), any locally available immune modulators, and any other therapeutic or preventive hcc vaccine. subjects requiring concurrent participation in another experimental research treatment study, or who received an experimental agent within four weeks prior to study entry. evidence of active or acute cardiac disease, epilepsy, or life-threatening diseases unrelated to hcc. medical conditions such as active alcohol or substance abuse, or psychological issues that in the opinion of the local investigator would interfere with adherence to the requirements of this study. -

Keywords: afp alpha-fetoprotein cancer vaccine cirrhosis hepatitis hcc hepatocellular carcinoma immunotherapy liver tumor cholangiocarcinoma
lessening incontinence by learning yoga

Conditions: Urinary Incontinence; Stress Urinary Incontinence; Urge Urinary Incontinence; Over Active Bladder

Summary: the purpose of this study is to assess the feasibility of recruiting women with urinary incontinence into a randomized controlled trial of a yoga therapy program.


Eligibility criteria:
inclusion criteria: * women aged 40 years or older who report urinary incontinence for \> 3 months prior to screening * self-report at least 7 urinary incontinence episodes per week on a screening 7-day voiding diary * self-report urgency-predominant, stress-predominant, or mixed-type incontinence on the screening voiding diary * willing to refrain from initiating medical treatments that may affect their incontinence or voiding pattern during the study period * capable of understanding study procedures and giving informed consent exclusion criteria: * participation in a yoga class or other formal or organized yoga instruction in the past year * any prior yoga therapy directed specifically at improving urinary incontinence or pelvic floor dysfunction * current use of medical therapy or device (i.e. pessary) for incontinence or use within the previous month * currently pregnant, gave birth within the past 6 months, or planning pregnancy during the study period * current urinary tract infection or a history or 3 or more urinary tract infections in the preceding year * report history of neurologic conditions such as stroke, multiple sclerosis, spinal cord injury, or parkinson's disease, or a lumbosacral spine condition associated with neurological symptoms * unable to walk up a flight of stairs or at least 2 blocks on level ground without assistance * unable to get up from a supine to a standing position in 10 seconds or less and without assistance * severe obesity, defined as body mass index \> 35 kg/m2 on screening examination * report history of interstitial cystitis, fistula or hole in bladder or rectum, or birth defect leading to urine leakage * report any history of prior anti-incontinence or urethral surgery (not including urethral dilation), pelvic cancer, or pelvic irradiation for any reason * report use of bladder botox, electrostimulation, bladder training, or pelvic floor exercise training (with certified practitioners) in the past 3 months * report other surgery to the pelvis (hysterectomy, oophorectomy, vaginal surgery, bladder surgery, colon surgery) within the past 3 months * report symptomatic pelvic organ prolapse * report history of vulvodynia, chronic pelvic pain, or pain when practicing pelvic floor exercises * report conditions that, in the judgment of the investigators, render potential participants unlikely to follow the protocol, including plans to move, substance abuse, significant psychiatric problems, or dementia * participation in another research study that involves investigational drugs or devices that could potentially confound the results of this study
doppler evaluation of ultrasound-guided pectointercostal fascial plane block in cardiac surgery

Conditions: Cardiovascular Surgery

Summary: the aim of this study was to evaluate the effect of pectointercostal fascial plane block on regional haemodynamic parameters in patients undergoing cardiac surgery.

perioperative pain management has become an important component of enhanced recovery after surgery (eras) protocols in patients undergoing cardiac surgery. pain is most intense in the first two days after cardiac surgery. inadequate pain control has been shown to cause an increase in pulmonary complications due to inadequate mobility and coughing, an increase in sympathetic activation, an increase in myocardial infarction and thromboembolic events, delayed wound healing, and prolonged hospital and intensive care unit stay. non-steroidal anti-inflammatory drugs (nsaids), paracetamol, opioids, epidural anesthesia and ultrasound-guided fascial plane blocks are widely used for pain management after cardiac surgery. the pectointercostal fascial plane (pifp) block is an ultrasound-guided, superficial fascial plane block that can be applied as part of multimodal postoperative analgesia, especially after cardiac surgery. pifb block has been shown to reduce postoperative analgesic consumption and improve pain scores not only in patients undergoing cardiac surgery but also in non-cardiac surgeries and thoracic procedures. the aim of this study was to evaluate the effect of pifp block on regional haemodynamic parameters in patients undergoing cardiac surgery.

Eligibility criteria:
inclusion criteria: * elective cardiac surgery * over 18 years, adult * american society of anaesthesiology (asa) i-iii exclusion criteria: * history of cerebrovascular disease * history of alzheimer's disease * mental disorder * emergency surgery * re-operated due to surgery-related complications * allergy to local anaesthetics * declining to give written informed consent

Keywords: regional anesthesia postoperative pain doppler ultrasound cardiovascular surgery